发布求助
文献互助 智能选刊 最新文献

Dermatology Reports最新文献

筛选
英文 中文
Facial pruritic skin rash in a Nigerian boy with atopic dermatitis. 尼日利亚一名男孩面部瘙痒性皮疹伴特应性皮炎。
IF 1.1
Dermatology Reports Pub Date : 2023-06-06 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9584
Gianmaria Viglizzo, Astrid Herzum, Lodovica Gariazzo, Corrado Occella
{"title":"Facial pruritic skin rash in a Nigerian boy with atopic dermatitis.","authors":"Gianmaria Viglizzo,&nbsp;Astrid Herzum,&nbsp;Lodovica Gariazzo,&nbsp;Corrado Occella","doi":"10.4081/dr.2023.9584","DOIUrl":"10.4081/dr.2023.9584","url":null,"abstract":"<p><p>We present the case of a 4-year-old boy with annular, pruritic macules on the face who did not respond to the application of topical immunosuppressive therapy for atopic dermatitis. In this case report, we emphasize how pruritic annular macules that are not responsive to immunosuppressants should always be suspected of being tinea incognita.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9584"},"PeriodicalIF":1.1,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/10/dr-15-3-9584.PMC10563027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modified H-plasty in large basal cell carcinoma defect reconstruction on the forehead. 改良H型成形术在前额大基底细胞癌缺损重建中的应用。
IF 1.1
Dermatology Reports Pub Date : 2023-06-05 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9677
Novita, Khairuddin Djawad
{"title":"Modified H-plasty in large basal cell carcinoma defect reconstruction on the forehead.","authors":"Novita,&nbsp;Khairuddin Djawad","doi":"10.4081/dr.2023.9677","DOIUrl":"https://doi.org/10.4081/dr.2023.9677","url":null,"abstract":"<p><p>Basal cell carcinoma (BCC) is the most common malignancy worldwide. Surgical removal is considered the gold standard treatment. However, large defects following excisional surgery can pose a significant challenge for reconstruction, especially in cases where primary closure is not possible. In these cases, skin flaps may be used. Most traditional skin flaps are limited by design to take advantage of only one region of relative skin excess. This paper reports a case of a large forehead defect following BCC excision that was successfully reconstructed by a modified Hplasty involving a U-plasty and rotation-advancement flap. Maintenance of aesthetics without impaired function is the aim of closure defects with combined flaps.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9677"},"PeriodicalIF":1.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/b0/dr-15-3-9677.PMC10563029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A case of perifolliculitis capitis abscedens et suffodiens and acne conglobata treated effectively with a TNF-α inhibitor TNF-α抑制剂有效治疗头毛囊周围炎、脓肿性和多发性痤疮1例
IF 1.1
Dermatology Reports Pub Date : 2023-06-05 DOI: 10.4081/dr.2023.9699
Shinpei Miura, Kanako Tsunoda, H. Amano
{"title":"A case of perifolliculitis capitis abscedens et suffodiens and acne conglobata treated effectively with a TNF-α inhibitor","authors":"Shinpei Miura, Kanako Tsunoda, H. Amano","doi":"10.4081/dr.2023.9699","DOIUrl":"https://doi.org/10.4081/dr.2023.9699","url":null,"abstract":"Perifolliculitis capitis abscedens et suffodiens (PCAS) and acne conglobate (AC) are often treated with isotretinoin and tumor necrosis factor alpha (TNF-α) inhibitors in Europe and the United States. Treatment with these drugs is uncommon in Asia, and alternative treatment options are limited. In this paper, we report the case of a Japanese patient who presented with PCAS and AC and was treated successfully with adalimumab.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"1 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70147943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A unilateral linear pattern of lichen planus pigmentosus. 色素性扁平苔藓的单侧线状模式。
IF 1.1
Dermatology Reports Pub Date : 2023-05-23 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9650
Amal Aboud Alasmari, Latifah Ibrahim Albrahim, Majed Aleissa
{"title":"A unilateral linear pattern of lichen planus pigmentosus.","authors":"Amal Aboud Alasmari,&nbsp;Latifah Ibrahim Albrahim,&nbsp;Majed Aleissa","doi":"10.4081/dr.2023.9650","DOIUrl":"10.4081/dr.2023.9650","url":null,"abstract":"<p><p>Lichen planus pigmentosus (LPP) is a rare chronic variant of lichen planus. LPP distribution tends to be symmetrical and is frequently seen on the face, neck, and trunk. Atypical clinical patterns of LPP, including segmental, zosteriform, and linear, were reported in the literature. Herein, we report a rare presentation of LPP in a 16- year-old female with a unilateral linear pattern along the Blascko lines.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9650"},"PeriodicalIF":1.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/b8/dr-15-3-9650.PMC10563022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atopic dermatitis: a brief review of recent advances in management 特应性皮炎:近期治疗进展的简要回顾
IF 1.1
Dermatology Reports Pub Date : 2023-05-23 DOI: 10.4081/dr.2023.9678
S. Alenazi
{"title":"Atopic dermatitis: a brief review of recent advances in management","authors":"S. Alenazi","doi":"10.4081/dr.2023.9678","DOIUrl":"https://doi.org/10.4081/dr.2023.9678","url":null,"abstract":"Atopic dermatitis (AD) is a common inflammatory skin disorder characterised by recurrent eczematous lesions and intense itch. The disorder affects people of all ages and ethnicities, has a substantial psychosocial impact on patients and relatives, and is the leading cause of the global burden from skin disease. Atopic dermatitis is associated with an increased risk of multiple comorbidities, including food allergy, asthma, allergic rhinitis, and mental health disorders. The pathophysiology is complex and involves a strong genetic predisposition, epidermal dysfunction, and T-cell driven inflammation. Although type-2 mechanisms are dominant, there is increasing evidence that the disorder involves multiple immune pathways. Until recently, the management of AD rested mainly on the judicious use of emollients, topical steroids, and topical calcineurin inhibitors in the majority of patients and systemic immunosuppressants were advocated in severely diseased. However, in the last few years, new therapeutic strategies were designed and developed to target the various steps in the chain of molecular events that lead to the AD phenotype. This review highlights the recent advancements in the management of AD.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47936110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent giant cellulitis-like sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine 严重急性呼吸系统综合征冠状病毒2型辉瑞-BioNTech信使核糖核酸疫苗诱导的复发性巨大蜂窝组织炎样甜味综合征
IF 1.1
Dermatology Reports Pub Date : 2023-05-23 DOI: 10.4081/dr.2023.9668
P. Hirt, Lily Park, Carly E. Wallace, F. Kerdel
{"title":"Recurrent giant cellulitis-like sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine","authors":"P. Hirt, Lily Park, Carly E. Wallace, F. Kerdel","doi":"10.4081/dr.2023.9668","DOIUrl":"https://doi.org/10.4081/dr.2023.9668","url":null,"abstract":"Primary and booster vaccines for COVID-19 are the most effective method of preventing infection and are generally considered safe. However, many cutaneous adverse events have been reported following vaccination. To date there have been seven reported cases of Sweet syndrome occurring following the first dose of the SARS-CoV-2 vaccine. We describe a rare case of atypical giant-cellulitis like Sweet syndrome reemerging after receiving the SARS-CoV-2 booster vaccine.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46782271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with mask-induced dermatosis and its impact on patients' quality of life. 口罩引发皮肤病的相关因素及其对患者生活质量的影响。
IF 1.1
Dermatology Reports Pub Date : 2023-05-23 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9694
Thuy Luong Nguyen Dac, Trang Vu Thi Thuy, Anh Le Dang Mai, Lien Nguyen Thi Bich, Tam Huynh Thi Xuan
{"title":"Factors associated with mask-induced dermatosis and its impact on patients' quality of life.","authors":"Thuy Luong Nguyen Dac,&nbsp;Trang Vu Thi Thuy,&nbsp;Anh Le Dang Mai,&nbsp;Lien Nguyen Thi Bich,&nbsp;Tam Huynh Thi Xuan","doi":"10.4081/dr.2023.9694","DOIUrl":"10.4081/dr.2023.9694","url":null,"abstract":"<p><p>The COVID-19 pandemic continues to have a significant impact on society, both physically and mentally. Mask use in public places has been made mandatory in many countries, as it is one of the most effective methods to prevent transmission of the virus. However, continuous mask usage has been associated with the emergence of various cutaneous diseases in the areas of contact with the mask. This study aimed to evaluate the effect of various cutaneous manifestations resulting from mask use on patients' quality of life through a questionnaire survey. This was a cross-sectional study conducted at a hospital from May to July 2022. Patients who had experienced skin symptoms related to mask use in the past or present were included in the study. Participants completed the questionnaire with informed consent. A total of 165 participants participated in the survey, with the most common complaint being itching (58.18%), followed by acne (52.73%). Itching was found to have the highest dermatology life quality index score. Patients with skin redness had a lower quality of life compared to those without it. Prolonged mask-wearing can result in skin diseases that can seriously impair patients' quality of life.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9694"},"PeriodicalIF":1.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/6d/dr-15-3-9694.PMC10563030.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is the most accurate naming convention: cutaneous lipofibroma or pedunculated lipofibroma? 什么是最准确的命名惯例:皮肤脂肪纤维瘤还是带蒂脂肪纤维瘤?
IF 1.1
Dermatology Reports Pub Date : 2023-05-23 DOI: 10.4081/dr.2023.9675
M. Al-Haddab
{"title":"What is the most accurate naming convention: cutaneous lipofibroma or pedunculated lipofibroma?","authors":"M. Al-Haddab","doi":"10.4081/dr.2023.9675","DOIUrl":"https://doi.org/10.4081/dr.2023.9675","url":null,"abstract":"We report a case of large pedunculated lipofibroma on left axilla in 36 year old woman, the lesion was excised completely with no recurrence after one year follow up. We propose a new name for this rare entity to be more inclusive of all lesions of pedunculated lipofibroma and to differentiate it from the other entity called fibrolipoma.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47906951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pemphigus vulgaris mimicking Steven-Johnson syndrome/toxic epidermal necrolysis: report of an unusual case. 类似Steven Johnson综合征的寻常性天疱疮/中毒性表皮坏死松解症：一例不寻常病例的报告。
IF 1.1
Dermatology Reports Pub Date : 2023-05-23 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9649
Latifah Albrahim, Amal Aboud Alasmari, Majed Aleissa
{"title":"Pemphigus vulgaris mimicking Steven-Johnson syndrome/toxic epidermal necrolysis: report of an unusual case.","authors":"Latifah Albrahim,&nbsp;Amal Aboud Alasmari,&nbsp;Majed Aleissa","doi":"10.4081/dr.2023.9649","DOIUrl":"10.4081/dr.2023.9649","url":null,"abstract":"<p><p>Pemphigus vulgaris (PV) is an autoimmune blistering disease affecting the skin and mucosa. It clinically presents as painful erosions, mainly in the oral cavity, and flaccid blisters and erosions on the skin. Steven-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe mucocutaneous drug hypersensitivity reaction characterized by painful, dusky, erythematous eruptions that often progress to blisters, erosions, and extensive epidermal detachment accompanied by systemic symptoms. Herein, we report the case of a 48-year-old man who presented with extensive skin and mucosal lesions following the ingestion of an unknown medication. The patient's symptoms clinically mimicked SJS, and accordingly, a preliminary diagnosis of SJS/TEN was made. However, clinical investigation of skin biopsy and direct immunofluorescence assay results indicated PV, and a final diagnosis of PV was established.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9649"},"PeriodicalIF":1.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/aa/dr-15-3-9649.PMC10563021.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study. 抗白介素-17和抗白介素-23生物药物治疗生殖器银屑病：一项单中心回顾性比较研究。
IF 1.1
Dermatology Reports Pub Date : 2023-05-19 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9692
Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti
{"title":"Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study.","authors":"Andrea Cortese,&nbsp;Luigi Gargiulo,&nbsp;Luciano Ibba,&nbsp;Giovanni Fiorillo,&nbsp;Francesco Toso,&nbsp;Carlo Alberto Vignoli,&nbsp;Alessandra Narcisi,&nbsp;Antonio Costanzo,&nbsp;Mario Valenti","doi":"10.4081/dr.2023.9692","DOIUrl":"https://doi.org/10.4081/dr.2023.9692","url":null,"abstract":"<p><p>Genital psoriasis affects 3-33% of patients with psoriasis during the course of the disease, usually leading to a severe reduction in the patient's quality of life. This study aims to retrospectively assess the effectiveness of interleukin (IL)-23 and IL-17 inhibitors in a real-life population affected by moderate-to-severe plaque psoriasis with genital involvement coming from our dermatology department. A total of 86 patients with a diagnosis of moderate-tosevere plaque psoriasis with severe genital involvement were enrolled. Patient characteristics, psoriasis area and severity index (PASI), and static physician global assessment of genitalia (sPGAG) at each visit were recorded. During the treatment, the mean PASI decreased from 12.8 to 0.63 at week 52; a PGA of 0/1 was reached by 97.40% at week 52 and by 100% of patients (37/37) at week 104. No significant differences between IL-23 and IL-17 inhibitors were observed; indeed, the bio-naïve group of patients demonstrated a superior response compared to the group of bioexperienced patients.Our findings confirmed that IL-23 and IL-17 inhibitors are safe and effective therapeutic options for the treatment of genital psoriasis.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9692"},"PeriodicalIF":1.1,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/9b/dr-15-3-9692.PMC10543193.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41116199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信